CONTACT US

GLP-1 Attorney for Telehealth Platforms, Compounders, and Weight Loss Clinics

CONTACT OUR FIRM
OUR STORY
CONTACT US

The GLP-1 market has exploded in recent years and with that growth has come an increasingly complex web of federal and state regulations that can expose unprepared businesses to serious legal risk. From U.S. Food & Drug Administration (FDA) enforcement actions targeting compounding pharmacies to state medical board scrutiny of telehealth prescribing practices, operators in the GLP-1 space face compliance challenges that require specialized legal counsel. 

At LumaLex Law, our attorneys work within the intersection of healthcare, pharmaceutical, and digital health law, giving our clients the focused representation that this rapidly evolving space demands. Our legal team helps GLP-1 businesses structure their operations for compliance, respond to regulatory scrutiny, and stay ahead of policy changes before they become liability. If you have questions about where your business stands, contact us today.

The Legal Landscape Surrounding GLP-1 Medications

Glucagon-like peptide-1 receptor agonists, commonly known as GLP-1 medications, were originally developed to manage type 2 diabetes. When clinical data confirmed their effectiveness for weight loss, demand surged well beyond what branded manufacturers could supply. That shortage opened the door for compounding pharmacies to legally produce copies of semaglutide and tirzepatide, and an entire industry of telehealth weight loss platforms emerged to prescribe and deliver them at scale.

How GLP-1 Medications Became a Regulatory Focus

The rapid commercial expansion caught the attention of regulators. The FDA, FTC, state pharmacy boards, and medical licensing agencies all began scrutinizing how GLP-1 products were being compounded, marketed, prescribed, and sold. What was once a relatively low-visibility area of pharmaceutical law quickly became one of the most actively enforced spaces in healthcare regulation.

The End of FDA Shortage Status for Semaglutide and Tirzepatide

The FDA’s removal of semaglutide and tirzepatide from its drug shortage list marked a turning point for the compounding industry. Under federal law, 503A and 503B compounders were permitted to produce copies of these drugs while a shortage existed. With the shortage designation lifted, that legal basis has narrowed significantly, and compounders who continue producing these medications without meeting specific criteria are operating in legally precarious territory.

The transition has not been clean. Litigation, guidance documents, and ongoing enforcement actions have created a patchwork of compliance obligations that vary depending on compounder classification, patient-specific factors, and state law. Businesses that were operating lawfully one year may face significant exposure today without even realizing it.

Why Compliance Matters More Than Ever in 2026

Federal and state enforcement agencies have made GLP-1 compliance a visible priority. FDA warning letters, FTC actions over deceptive marketing, cease-and-desist letters from brand manufacturers, and state board investigations are all on the rise. For businesses in this space, proactive legal counsel is no longer optional. Contact LumaLex Law to speak with a GLP-1 attorney about where your operation stands.

Our GLP-1 Legal Services

LumaLex Law provides comprehensive legal services to businesses across the GLP-1 supply and delivery chain. Our work includes:

  • FDA compounding compliance under Sections 503A and 503B
  • Telehealth platform structuring and corporate compliance
  • Prescribing protocol review and clinical documentation guidance
  • Marketing and advertising compliance under FTC and FDA standards
  • Drug shortage analysis and compounding eligibility assessments
  • State pharmacy board and medical board compliance
  • Investor due diligence and healthcare transactional support
  • Response to warning letters, subpoenas, and enforcement actions
  • Privacy and data security compliance under HIPAA

Who We Represent in the GLP-1 Space

Our clients operate across the full spectrum of the GLP-1 industry, including:

  • Compounding pharmacies operating under 503A or 503B designations
  • Telehealth platforms prescribing GLP-1 medications to patients nationwide
  • Medical spas and weight loss clinics offering injectable GLP-1 therapies
  • Digital health companies building GLP-1-adjacent products and platforms
  • Private equity firms and investors conducting due diligence on GLP-1 businesses
  • Physicians and nurse practitioners building independent GLP-1 practices

Federal and State Laws Governing GLP-1 Operations

GLP-1 businesses must navigate a layered regulatory environment. The legal frameworks most likely to affect your operation include:

  • The Federal Food, Drug, and Cosmetic Act and its compounding provisions
  • FDA guidance documents on bulk drug substances and shortage compounding
  • FTC regulations governing health claims and advertising
  • DEA registration requirements where applicable
  • State pharmacy practice acts and board regulations
  • State medical practice acts governing telehealth prescribing
  • HIPAA and state privacy laws applicable to digital health platforms
  • Corporate practice of medicine doctrines that vary by state

Failure to understand how these frameworks interact can result in enforcement actions, license revocations, civil litigation, and in serious cases, criminal liability.

FDA Regulations

FDA compounding compliance under Sections 503A and 503B is a cornerstone of what we do for GLP-1 clients. 

Section 503A governs traditional compounding pharmacies that produce medications for individual patients based on a valid prescription. 

Section 503B governs outsourcing facilities that produce larger batches without patient-specific prescriptions and are subject to more rigorous FDA oversight. 

The rules that apply to your business, what you can produce, how it must be labeled, and what records you must maintain depend heavily on which category you fall into and whether the underlying drug remains in shortage. We help clients understand exactly where they stand and build compliance programs that hold up under scrutiny.

High-Risk Areas in GLP-1 Business Models

Certain aspects of GLP-1 business operations draw disproportionate regulatory attention. Businesses should pay close attention to the following risk areas:

  • Compounding after the shortage designation ends without a qualifying exemption.
  • Marketing compounded GLP-1 products using branded drug names like Ozempic or Wegovy.
  • Making efficacy or safety claims that have not been substantiated by clinical evidence.
  • Operating subscription or membership models that may implicate fee-splitting or insurance laws.
  • Prescribing via asynchronous telehealth in states that require synchronous evaluations.
  • Failing to maintain adequate clinical documentation to support prescribing decisions.
  • Using non-physician business structures in states with strict corporate practice of medicine rules.

If any of these apply to your current model, contact our team before a regulatory agency contacts you first.

Responding to Enforcement Actions and Litigation

When a GLP-1 business receives a warning letter, cease-and-desist, or notice of investigation, the response window is narrow and the stakes are high. Acting without experienced legal counsel often makes outcomes worse. LumaLex Law assists clients with:

  • Analyzing the legal basis of enforcement actions
  • Drafting formal responses to FDA, FTC, and state agencies
  • Negotiating consent agreements or corrective action plans
  • Defending against civil litigation brought by brand manufacturers
  • Managing parallel state and federal enforcement proceedings

Early intervention gives businesses the best chance of reaching a resolution that protects their license, their operations, and their reputation.

Why GLP-1 Operators Choose LumaLex Law

GLP-1 businesses need attorneys who understand both the science and the law. Our regulatory compliance attorneys combine deep regulatory healthcare experience with practical knowledge of how telehealth, pharmacy, and digital health businesses actually operate. We do not apply a generic healthcare compliance template to every client. We build compliance strategies around the specific structure, scale, and risk profile of each business we represent.

We also understand the pace at which this industry moves. Regulatory guidance changes, enforcement priorities shift, and business models evolve. Our clients benefit from counsel that monitors those changes in real time and advises proactively rather than reactively. 

Speak with a GLP-1 Attorney About Your Compliance Strategy

The regulatory environment around GLP-1 medications will continue to evolve throughout 2026 and beyond. Whether you are building a new business, reassessing an existing operation, or responding to a legal threat, the time to act is now. Contact LumaLex Law to schedule a consultation with a GLP-1 attorney today.

GLP-1 Compliance FAQs

The answer depends on several factors, including whether your pharmacy operates under 503A or 503B, the current FDA shortage designation status, and whether the specific drug or its base compound appears on the FDA's list of bulk drug substances. The landscape has shifted significantly since the shortage removal, and what was permissible in 2024 may not be permissible today. Speak with a GLP-1 attorney to assess your current eligibility.

Do not ignore it and do not respond without legal counsel. Cease-and-desist letters from regulatory agencies or brand manufacturers typically have short response deadlines and can carry significant legal consequences if handled improperly. Contact LumaLex Law as soon as possible so we can evaluate the letter and advise on the appropriate response.

Yes. The FDA regulates both labeling and promotional claims for compounded drugs. The FTC also has authority over deceptive advertising, including unsubstantiated weight loss claims. Businesses that market compounded semaglutide or tirzepatide using comparative claims, clinical statistics, or branded drug references may be exposing themselves to enforcement risk.

Semaglutide and tirzepatide are not currently classified as controlled substances, so DEA registration is not required specifically for those drugs. However, if your practice or platform also prescribes medications that are controlled substances, such as certain appetite suppressants, DEA registration and compliance obligations apply to those aspects of your operation.

In many states, yes, but with important limitations. Corporate practice of medicine doctrines in states like California, Texas, and New York restrict the ability of non-physicians to own entities that practice medicine or employ physicians in certain structures. Proper structuring, typically through a management services organization model, is essential for investor-backed or non-physician-owned telehealth platforms operating in these states. 

Ian Horowitz

Ian Horowitz

Of-Counsel
States Licensed: FL

Mr. Horowitz focuses his practice on estate planning, taxation, and business related matters, with advanced proficiency in estate, gift, federal income, and generation-skipping transfer taxation. His extensive knowledge in these areas enables him to craft tailored strategies that optimize tax efficiency and safeguard his clients’ assets. From crafting straightforward wills to designing complex domestic and foreign trusts, his commitment to preserving wealth and ensuring asset protection is unwavering.

In addition to his prowess in estate planning, Mr. Horowitz serves as a trusted advisor to businesses of all sizes from formation to sale assisting with drafting purchase and sale agreements, limited liability operating agreements, or other corporate documents. His counsel on entity formation and tax-efficient structures empowers entrepreneurs and corporations to make informed decisions that drive growth and prosperity.

Mr. Horowitz possesses a wealth of experience in international tax matters. He offers invaluable guidance to foreign clients navigating inbound business and real estate transactions in the United States. He is also recognized for his efficiency in helping individuals become bona fide residents of Puerto Rico under IRC Section 937. This specialized knowledge in tax strategies related to Puerto Rico’s unique tax laws positions him as a sought-after advisor for those seeking to take advantage of the favorable tax incentives offered by Puerto Rico.

Aggeliki Psonis

Aggeliki Psonis

Associate
States Licensed: NY, NJ. MA

A graduate of Boston University, with a JD from CUNY law school, Aggeliki focuses her practice on real estate transactions, estate planning and administration, business law and general litigation. She has extensive experience representing buyers, sellers, investors and business owners based in New York and internationally.

Aggeliki is admitted in the states of New York, New Jersey and Massachusetts, as well as in the Eastern and Southern Districts of New York. She is also a licensed Real Estate broker. She is a proud member of the Inspiring Women in Law League (IWILL) and the Hellenic Lawyers Association. She speaks fluent Greek and conversational French and Spanish. Aside from lawyering, she enjoys being a radio producer and performing artist.

Dallas Robinson, Of-Counsel

Dallas Robinson

Of-Counsel
States Licensed: FL

 

Dallas Robinson is an AV Preeminent-rated trial attorney who has dedicated his practice to representing injured people throughout Florida. Dallas has litigated and tried many different types of personal injury cases in numerous courthouses and venues in Florida. Dallas believes in prosecuting personal injury cases in a professional and aggressive manner, and has a clear track record of success in obtaining great financial compensation for his clients either through verdicts or settlements. Many lawyers advertise ‘trial experience,’ but have actually never seen the inside of a courtroom. Dallas has spent his entire career in the courtroom and litigating cases. This gives Dallas the real and true experience that it takes to strike fear in the hearts of insurance companies and obtain top financial compensation for his injured clients.

 

Dallas grew up in South Florida and attended Boston University where he played quarterback and defensive back for Boston University’s football team. Dallas graduated in 4 years with bachelor degrees in Classical Civilizations and History. He went straight to law school and attended University of Miami (FL) School of Law. Dallas graduated in 2002 with a Juris Doctorate degree and immediately passed the Florida Bar.

 

Dallas began his legal career representing businesses and insurance companies in workers’ compensation and personal injury cases. This gave him unique insight into exactly how insurance companies work and how they value cases. After achieving a high level of success in litigating these cases, Dallas moved on to representing the injured. Since that time, Dallas has obtained tens of millions of dollars in compensation for his clients through settlements and trial verdicts. Dallas is a member of the Multi-Million Dollar Advocates Forum which is an association of attorneys who have won seven-figure verdicts and settlements on behalf of their clients. This group is one of the most prestigious organizations for trial lawyers in the United States as fewer than 1% of U.S. lawyers have qualified as members.

 

In addition to great results for his clients, Dallas has also gained the respect of his peers for his ethics, ability, and professionalism. Dallas has received the highest level of distinction of an AV ® rated attorney by Martindale-Hubbell, which recognizes Dallas as possessing “Very High-Preeminent” legal ability with “Very High” ethical standards.

Yisroel Szpigiel, Of-Counsel

Yisroel Szpigiel

Of-Counsel States Licensed: NY, NJ  
Yisroel Szpigiel is a NY/NJ corporate attorney focused on outside general counsel and commercial transactions. With nearly a decade of experience managing law firms, he represents entrepreneurs, investors, and some of New York’s largest real estate developers in matters ranging across the full business lifecycle– from entity formation and early stage growth to day-to-day commercial contracting to complex financings, acquisitions, and strategic exits. He has closed over $100 million in transactions and is known for practical, business-first legal guidance that protects clients while keeping deals moving. 
 
Since joining LumaLex Law as Managing Partner January 2025, Yisroel has grown the firms Commercial Transactional and Real Estate Practices, and has started the firms MSO practice, focusing on private equity healthcare rollups. Yisroel is best known as a “problem solver”, with the ability to turn complex problems into workable solutions. He was twice named as a Super Lawyers New York Rising Star in 2024 and 2025, in the practice areas of Business Law, Real Estate, Mergers and Acquisitions, and Plaintiff’s Personal Injury.

In addition to his work with LumaLex Law and serving as trusted outside counsel to businesses in a wide range of industries, he has been recognized by community leaders with citations and awards. Yisroel earned his undergraduate degree from Rutgers University and his J.D. from Hofstra University School of Law, where he later returned as an adjunct professor. Outside the office, he enjoys golf, pickleball, and traveling with his wife and three children. 
Tom Dean | Of-Counsel

Tom Dean

Of-Counsel 
States Licensed: AZ

 

Tom Dean has been an attorney advocate for nationwide cannabis policy reform for over 25 years. As Legal Director for the National Organization for the Reform of Marijuana Laws (NORML) he initiated, managed, and litigated important cannabis related cases of national importance to the cannabis industry/community. In that capacity, he also coordinated the efforts of the NORML Legal Committee (lifetime member) and NORML Amicus Committee (former chair) in key cases throughout the U.S.  In 2015 the organization recognized his successful advocacy by inducting him into the NORML Distinguished Counsel’s Circle. He remains an active member of the NORML Legal Committee.

In 2016, Tom received the President’s Commendation award from the Arizona Attorneys for Criminal Justice (AACJ). In 2020, Tom received a Lifetime Achievement Award from the Errl Cup, a medical marijuana event producer which includes Arizona’s premier cannabis awards festival (30,000 attendees this year).

In 2021, Tom received Mikel Weiser Lifetime Achievement Award from Arizona’s Marijuana Industry Trade Association (MITA). Most recently, in 2023, Tom was honored by NORML with its Al Horn Award, which the organization awards to an attorney each year to in “recognition of a lifetime of ceaseless work to advance the cause of justice” in cannabis law.

Tom was a founding member of the Arizona Cannabis Bar Association (ACBA), an organization that seeks to educate lawyers and the public of the many unique aspects of cannabis law and emerging cannabis related areas of practice. He continues to serve on the board of ACBA. Outside of his practice, Tom enjoys, among other things, presenting at cannabis related seminars and conferences for lawyers and the public.

Josh Sanderlin | Of Counsel

Joshua Sanderlin

Of Counsel
States Licensed: MD, D.C.

Joshua Sanderlin is an experienced cannabis attorney and government affairs expert barred in Maryland and the District of Columbia. He has worked in the cannabis industry since 2013. At that time, he was an attorney and lobbyist at a large, global law firm. His experience working with clients in the earliest legal cannabis market in the U.S. sparked his interest in the field and motivated him to leave big law for the world of cannabis.

Since then, he has served as a lawyer and consultant to clients working in markets across the country, including seven states and the District of Columbia. His experience has given him a wide breadth of knowledge on issues touching the industry and, just as importantly, expanded his network to include experts from all across the industry. Having worked on cannabis issues in a variety of settings, Joshua understands that the industry is best served by specialized services.

Edgar J. Asebey | Of Counsel

Edgar J. Asebey

Of Counsel
States Licensed: FL, D.C.

 

Edgar J. Asebey is a regulatory and transactional attorney with over two decades of experience in federal regulation of pharmaceutical, biotechnology, medical device, food, dietary supplement and cosmetics companies. Since 2015, he has been working on Cannabis-related matters and transactions and since 2018 he has provide regulatory compliance, business transactional, venture finance and international trade services to hemp/CBD companies. Edgar brings a wealth of knowledge and over 20 years of experience to life science, Cannabis and hemp/CBD clients who require novel solutions to complex issues.

Edgar practices before the Food and Drug Administration (FDA), United States Department of Agriculture (USDA), Customs and Border Protection (CBP), Environmental Protection Agency (EPA), and the Federal Trade Commission (FTC), representing client companies on regulatory compliance, product approval/registration and FDA enforcement defense matters. He also assists clients with international and domestic business transactions, IP licensing, venture finance, trademark protection and import/export matters.

Edgar studied molecular biology at the University of Chicago and spent 5 years working in molecular biology research laboratories at the University of Chicago and the University of Illinois.  Early in his career he served as a Patent and Licensing Advisor to the Natural Products Branch of the National Cancer Institute at the National Institutes of Health (NIH).  He founded and served as president of Andes Pharmaceuticals, Inc., a natural products drug discovery company, from 1994 to 2000 and has served as in-house counsel to two life sciences companies. Most recently he was an equity partner in the Health Care & Life Sciences Practice Group at Jones Day. Edgar is currently a partner at Keller Asebey Life Science Law, PLLC.

While Edgar holds licenses to practice law in Florida and Washington, D.C. he can represent clients on federal regulatory matters in all 50 states.  He is a member of the American Bar Association (Section on Administrative Law & Regulatory Practice: Food and Drug Committee and International Committee), Food & Drug Law Institute (FDLI), Dade County Bar Association, and BioFlorida.

Dan Miller Head-Shot | Of-Counsel

Dan Miller

Of-Counsel
States Licensed: CA

Dan Miller, Esq., with over 15 years of experience in cannabis law and a growing expertise in psychedelics, is a staunch advocate for honoring both traditional and evolving regulated uses of these substances. A Vermont Law School alumnus (Class of 1998), he holds a J.D. and a Master’s in Environmental Law and Policy.

Before his foray into the world of entheogenic medicines, Dan honed his skills as a trial attorney with a focus on both criminal and civil cases. His passion for and in-depth understanding of cannabis and psychedelic substances redirected his career path, leading him to develop a niche practice area that has since become his hallmark.

Dan’s role in the cannabis industry is not just as a lawyer, but as a partner in his clients’ endeavors. He oversees all aspects of business development, from structural planning and licensing to adapting to dynamic legal landscapes. His strategic insights have been key in securing licenses, operational planning, and facilitating interstate business growth.

Dan continues to serve as outside general counsel for various businesses, leveraging his litigation background to offer comprehensive legal advice.

As the legal landscape continues to evolve, Dan Miller remains a steadfast and knowledgeable advocate, committed to bridging the gap between traditional use and modern regulatory frameworks in the world of cannabis and psychedelics.

States Licensed: CA

Christina Jaramillo | Junior Associate

Christina Jaramillo

Junior Associate
States Licensed: FL, CA

Christina Jaramillo is an Associate Attorney at LumaLex Law and an active member of The Florida Bar. Christina’s primary focus has been in the practice area of business transactions. Christina has legal experience drafting and reviewing various sales and services agreements, completing entity filings and EIN applications, drafting corporate governance documents and business plans, preparing franchise disclosure documents, drafting and reviewing commercial and residential lease agreements, assisting with mergers and acquisitions, preparing demand letters, working on estate plans and probate matters, and trademarks. Prior to joining LumaLex Law, Christina led the estate planning department at The Law For All, P.A.

Christina is the daughter of two Latinx immigrants, the youngest of five siblings, and the first member of her immediate family to graduate from college. In 2017, after just three short years on campus, Christina received her Bachelor of Science in Political Science, magna cum laude, from Florida State University, where she also minored in Economics. Christina received her Juris Doctor, magna cum laude, from the University of Miami School of Law in 2020.

While attending the University of Miami School of Law, Christina received several honors: Christina was nominated to serve as one of two Articles & Comments Editors for the University of Miami International and Comparative Law Review; Christina was a recipient of the Dean’s Certificate of Achievement Award, which is awarded to the top one or two students in the course, in Legal Communications & Research II; and Christina made the Dean’s List twice.

During her time in law school, Christina served as a Fellow and Blog Editor for the Professional Responsibility and Ethics Program (PREP), an intern for the Human Rights Clinic, and a Civil Procedure Dean’s Fellow. Christina was active on campus and engaged in her community because she understood the value in connecting with those around her and serving the needs of her community, which remains true today.

In her free time, Christina can be found at her local comic book shop or vegan bakery. Christina loves to read, stay up to date on popular television shows and movies, watch soccer, and occasionally jog.

Andy Sick | Partner

Andy Sick

Partner
States Licensed: NY, NJ, MI, CT

Andy Sick has been advising businesses, startups, and entrepreneurs for nearly 15 years. He assists clients through every stage of the business life cycle from incorporation and initial growth phases, to maturity with ongoing general counsel services including regulatory compliance and critical commercial transactions, and dissolution. Licensed to practice in New York, New Jersey, and Connecticut, Andy is the attorney responsible for the firm’s practice in these states.

At Mr. Cannabis Law, Andy represents various cannabis-related businesses on such matters as corporate structuring, licensing, and financing. He navigates clients through the constantly changing sea of cannabis rules and regulations. Andy handles marijuana license applications, business plans, and operating procedures for dispensaries, cultivators, nurseries, manufacturers, distributors, wholesalers, delivery services, and testing facilities. For the firm’s hemp industry clients, Andy helps obtain hemp licenses and maintain compliance with federal and state regulations. In the psychedelic space, Andy has served as a legal advisor to numerous non-profits, companies, and organizations including such groups as Decriminalize Nature and the Native American Church.

Andy began his legal career at boutique law firms serving as outside general counsel to businesses and representing clients in complex commercial litigation. Whether representing a three-person video game startup or a multinational spent nuclear fuel storage company, Andy worked directly with company presidents and other executives to develop and implement corporate legal strategies. Subsequently, he founded several startups, including a legal technology company that adapted artificial intelligence and virtual reality for use in the law. In addition to working with Mr. Cannabis Law, Andy has his own law firm, Sick Legal, which provides business and commercial transactional services to a range of clients.

During law school, Andy worked at the U.S. Justice Department’s Office of Consumer Litigation, the U.S. Attorney’s Office for the Northern District of New York, and for President Joe Biden when he served on the U.S. Senate Judiciary Committee

Andy is responsible for firm operations in New York, New Jersey, Michigan, and Connecticut 

Amanda Barton | Partner

Amanda Barton

Partner
States Licensed: FL

Amanda Barton is an active member of the Florida Bar and is admitted to practice in all U.S. District Courts and U.S. Bankruptcy Courts within the state of Florida.  Amanda has over ten years of legal experience handling complex corporate matters, with a strong focus on corporate governance, corporate finance, and regulatory compliance.  As someone who loves written language, Amanda excels in drafting and negotiating a vast array of legal documents.

Prior to joining LumaLex Law, Amanda had unique legal opportunities that have made her a well-versed, seasoned transactional business attorney.  Previously, she led the transactional department at The Law for All, P.A., where she assisted business clients with strategic business structuring, mergers and acquisitions, asset protection, business succession planning, and contract drafting, including companies involved in the cannabis and hemp industry.  She served as senior in-house counsel for an alternative financing company, where she built a legal department that leveraged technology, data analysis, and innovative resolution and recovery strategies.  Amanda also served as in-house counsel to a private investment firm, where she handled all in-house transactions with a concentration in Debtor-in-Possession financing for Chapter 11 debtors, secured lending transactions, fund management, and various aspects of municipal bond financing.

Amanda currently volunteers her time to serve as the President of the Broward County chapter of CannabisLAB, a networking and education group for professionals who are in or are looking to get involved in the cannabis marketplace.

Dustin Robinson | Managing Partner

DUSTIN ROBINSON

Founding Partner
States Licensed: FL

Dustin Robinson is the Founding Partner of LumaLex Law. Licensed in Florida as an Attorney, Certified Public Accountant, and Real Estate Agent, Robinson brings a rare, fully integrated legal–financial–business perspective to every engagement. His practice focuses on corporate structuring, regulatory strategy, transactions, capital formation, and high-stakes commercial litigation for growth-stage and emerging-market companies across a wide range of industries.

Before launching LumaLex Law, Robinson trained at two of the world’s most respected professional services firms—Deloitte and Holland & Knight—where he developed deep technical grounding in tax, corporate law, and complex commercial matters. He then left traditional practice to become an operator himself, applying his legal and accounting background to help run a multi-state manufacturing company that he helped grow to nearly $50 million in revenue. That experience shaped his core philosophy: great legal advice must be practical, entrepreneurial, and grounded in the realities of building and scaling real businesses.

Robinson is not only an advisor to entrepreneurs—he is one. In addition to LumaLex Law, he is the founder of multiple ventures, including Iter Investments , a venture capital fund backing frontier technologies and next-generation healthcare platforms; and Nucleus, a venture studio focused on launching digital and data-driven assets in emerging markets. Across his legal and investment platforms, Robinson has worked with founders operating in biotech, neurotech, telehealth, psychedelics, cannabis, fintech, real estate, digital media, AI-driven platforms, and other highly regulated or rapidly evolving sectors.

Widely regarded as a trailblazer in emerging industries, Robinson has played a leading role in shaping legal and commercial frameworks for novel business models long before they became mainstream. He has served as lead counsel in several high-profile commercial disputes, including the widely covered Shohei Ohtani 50–50 baseball litigation, and is frequently sought out for matters involving regulatory gray zones, innovative deal structures, and first-of-their-kind ventures.

Robinson also served on the Board of Directors of Clairvoyant Therapeutics, a biotechnology company that was advancing psilocybin-based treatments for alcohol use disorder through FDA clinical trials. He has advised and represented numerous venture-backed companies, founders, and investment vehicles operating at the intersection of science, technology, regulation, and capital markets.

Beyond legal practice and investing, Robinson is deeply involved in thought leadership and ecosystem-building. He created and moderates a long-running monthly panel series at Soho Beach House Miami, convening founders, physicians, scientists, investors, and cultural leaders to discuss innovation, wellness, and frontier technologies. Past guests have included NBA Champion Lamar Odom, NHL star Daniel Carcillo, and other prominent figures across business and entertainment.

Robinson has been regularly profiled and featured as an expert in major media outlets, including Bloomberg News, Forbes, The Wall Street Journal, INSIDER, VICE, The Miami Herald, Authority Magazine, Thrive Global, Benzinga, and others. He is a frequent speaker at global industry conferences and private founder and investor forums.

A triple Gator, Robinson earned his Bachelor’s in Accounting, Master’s in Accounting, and Juris Doctor from the University of Florida.

Today, Robinson’s work sits at the intersection of law, entrepreneurship, and capital formation. He is known for helping founders think bigger, structure smarter, and move faster—while staying compliant, investable, and defensible. His mission is simple: to help entrepreneurs build category-defining companies in industries that don’t yet have a playbook.